About
Antibodies to Cancer Stem Cell Receptors
TaGeza Biopharmaceuticals is a biotechnology start-up dedicated to the study of cancer stem cells in the deadliest forms of cancer. The company seeks to identify central markers of highly aggressive cancer stem cells and develop drugs to target them, with the goal of eradicating different forms of treatment-resistant cancers. TaGeza is a spin-off company of Tel Hashomer Medical Research, Infrastructure and Services Ltd, the technology transfer arm of Sheba Medical Center.
Identity
| Name | TaGeza Biopharmaceuticals |
|---|---|
| Slug | tageza-biopharmaceuticals |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoKXZscMIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Sep 2023 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Druyanov Street 5, Tel Aviv-Yafo, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareLaboratoriesPatients
Business models
B2B
Tags
drug-discoveryantibodiescancerbiopharmaceuticallaboratoriespharma-companies
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}